Food Lion earns LEED Silver certification for two Fayetteville, N.C., stores
SALISBURY, N.C. — Food Lion announced that two of its stores in Fayetteville, N.C., have earned LEED Silver certification from the U.S. Green Building Council.
The supermarket chain said the stores feature such environmentally friendly construction and energy-efficient services as an on-site recycling center, an educational kiosk and preferred parking for carpool vehicles.
"At Food Lion, we are committed to protecting the environment and reducing energy consumption through green building construction, and we are especially proud to have received this recognition," said Kyle Mitchell, VP store development for Delhaize America South. "We are honored to be recognized for these efforts and look forward to identifying other opportunities to build LEED stores and continuing to further reduce our energy consumption."
Wegmans debuts new store in Northborough, Mass.
NORTHBOROUGH, Mass. — Regional supermarket chain Wegmans made its New England debut on Oct. 16.
The chain opened a 138,000-sq.-ft. store, located in Northborough, Mass., which touts 70,000 products. Citing industry figures, Wegmans said the store is twice the average number for traditional grocery stores.
“We’re so proud to introduce Wegmans to New England we can hardly wait to open the doors,” Wegmans store manager Kevin Russell said. “We aim to give our new customers a shopping experience they’ll love… a real feast for the senses.”
Watson seeks approval for generic ADHD treatment
PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals is seeking Food and Drug Administration approval for a generic treatment for attention deficit hyperactivity disorder, the company said.
Watson announced that it filed a regulatory approval application with the FDA for methylphenidate transdermal system, a patch designed to deliver the central nervous system stimulant methylphenidate over a nine-hour period. The drug is a generic version of Noven Pharmaceuticals’ Daytrana.
Noven filed a patent infringement suit against Watson last week in the U.S. District Court for the District of New Jersey in response to the filing. Under the Hatch-Waxman Act, the suit puts a stay of FDA approval on Watson’s drug for 30 months, or until the Noven and Watson settle the matter. Watson is likely the first company to file for approval of a generic version of Daytrana and as such, will have 180 days in which to compete directly with Noven once it wins final FDA approval.
Daytrana had sales of more than $87 million during the 12-month period ended in July, according to IMS Health.